Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 19/20 | 0.77 |
| ▸ | PDE4A | P27815 | 2/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lixazinone SCHEMBL23630204 | 0.99 | PDE3B (0.76) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Lixazinone SCHEMBL122949 | 0.97 | PDE3B (0.72) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Lixazinone SCHEMBL29605513 | 0.84 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Lixazinone SCHEMBL7719533 | 0.84 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10374855 | 0.84 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10375017 | 0.84 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Lixazinone SCHEMBL10375012 | 0.84 | PDE3B (0.98) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10375980 | 0.83 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Lixazinone SCHEMBL10500635 | 0.83 | PDE3B (0.97) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10375015 | 0.83 | PDE3B (1.00) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 933 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2275095-A2 | Neurogenesis by muscarinic receptor modulation | Braincells, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2008-01-10 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| EP-0961616-A4 | NON-HORMONAL METHOD OF CONTRACEPTION | TRUSTEES OF BOARD OF (US) | 2000-11-22 | — | — | EP | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE3B 2328/4885PDE3A 2619/4885PDE4A 1173/4885 |
| US-20080009498-A1 | Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use | PDE3A, PDE3B, PDE2A | PDE3B 2/4885PDE3A 1/4885PDE4A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.